Market Research Logo

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
    • The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects
    • The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview
    Therapeutics Development
    Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview
    Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development
    Altor BioScience Corporation
    APIM Therapeutics AS
    Astellas Pharma Inc.
    Bavarian Nordic A/S
    BioCancell Ltd
    Celgene Corporation
    Cold Genesys, Inc.
    F. Hoffmann-La Roche Ltd.
    Heat Biologics, Inc.
    Merck & Co., Inc.
    Spectrum Pharmaceuticals, Inc.
    Taris Biomedical LLC
    UroGen Pharmaceuticals, Ltd.
    Vakzine Projekt Management GmbH
    Vaxiion Therapeutics, Inc.
    Viralytics Ltd.
    Viventia Bio Inc.
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ALT-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALT-803 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    apaziquone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atezolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BC-819 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Superficial Bladder Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cavatak - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG-0070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CV-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DAB-389EGF - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    docetaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for NMIBC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erlotinib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gemcitabine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imiquimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lenalidomide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mitomycin SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitroxoline - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-MAPA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rAd-IFN - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sirolimus albumin-bound - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VAX-014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VB-4845 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vesigenurtucel-L - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPM-1002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones
    Featured News & Press Releases
    Aug 10, 2016: TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Bladder Cancer
    May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016
    May 05, 2016: UroGen Pharma Announces Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting
    Apr 07, 2016: Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestone
    Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm
    Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation)
    Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold
    Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial
    Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
    Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset
    Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting
    Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting
    Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement
    Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer
    Jul 02, 2015: Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2016
    Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Merck & Co., Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Taris Biomedical LLC, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vaxiion Therapeutics, Inc., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Bio Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H2 2016
    Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2016
    Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report